Will 14 key categories of medical insurance catalog be big winners?

Source: sepiland think tank 2016-08-22 at present, the drug selection work of the medical insurance catalog has been started, and the Ministry of human resources and social security has formulated special documents, which have made clear provisions on the conditions, review procedures, adjustment mechanism, etc for medical insurance drugs As early as July 22 this year, a spokesman for the Ministry of human resources and social security said that the adjustment of the medical insurance drug catalogue will be the focus of this year The coverage rate of basic medical insurance in urban and rural areas in China has exceeded 95% About 1.34 billion people can get medical insurance reimbursement For pharmaceutical enterprises, if drugs can be included in the scope of medical insurance reimbursement, it will play a very positive role in promoting drug sales Therefore, this adjustment, from product sales to future development of the enterprise, will be greatly affected According to Li Zhong, spokesman of the Ministry of human resources and social security, the selected drugs are not submitted by enterprises, but generated based on the data of CFDA and medical and health departments In addition to the "clinical reasonable needs", three conditions will be considered in the screening scope: first, drugs that enter more than 15 provinces of the provincial medical insurance directory will automatically enter the selection directory; second, drugs that are included in various inquiry medical guidelines and clinical treatment guidelines will be included in the selection directory 3、 Whether the price performance ratio has advantages (including multi competitive products, domestic products with independent intellectual property rights, and products with long listing time and clinical recognition) Under strict screening conditions, which varieties will enter the medical insurance catalog and which will exit the medical insurance catalog are the real concerns of enterprises The national policy clearly puts forward that: according to the bearing capacity of medical insurance fund, drugs that meet the conditions, have reasonable prices and have independent intellectual property rights shall be included in the scope of medical insurance payment in time Therefore, no matter the national new drugs or the new star innovative drugs that have been on the market for a long time, they will be the biggest winners in the adjustment of the medical insurance catalogue this year Data source of key innovative drugs not listed in the national health insurance Catalogue: mineI Among the innovative drugs not listed in the national medical insurance catalogue, ceftriaxone sodium and tazobactam sodium for injection, cefotaxime sodium and Sulbactam Sodium for injection, novobin, Yilian, kailikang, kaidimidine, Kemena, Lanmu and aitan are all over 100 million varieties sold annually Among the over 100 million varieties sold in these years, Camry is the only domestic innovative drug that has passed the price negotiation of national medical insurance According to the data of Baida pharmaceutical prospectus, the sales volume of exetinib hydrochloride tablets in 2015 was 910 million yuan It is not only the catalog adjustment, but also the policy linkage This adjustment of the medical insurance catalog will not only bring about the impact of drugs entering or exiting the medical insurance catalog, but also consider the linkage with other policies In May, the national health and Family Planning Commission announced the results of the first batch of drug price negotiations Are these three varieties sure to enter the new medical insurance catalog? In theory, these three varieties are all in clinical demand The adjustment of the new version of the catalogue will be carried out in coordination with the national drug price negotiation, and these three varieties may be preferentially included in the medical insurance catalogue However, due to the price negotiation and the adjustment of medical insurance catalogue, which are led by two departments respectively, it may be necessary to consider comprehensively in terms of payment standards, etc According to the data, there are about 1000-1500 varieties in the new rural cooperative medical insurance catalogue of each province, while there are more than 2150 varieties in the medical insurance catalogue of urban residents According to the principle of "high but not low", the rural drug use will be greatly expanded All in all, the adjustment of the medical insurance catalogue has a great impact on enterprises After the adjustment of the national medical insurance catalogue, the provinces will adjust accordingly It will take time, and the impact on the sales of related products will lag behind What enterprises should do now is to link the adjustment of medical catalogue with more medical insurance policies, and think about how the pattern of China's medical market will change, and what should enterprises do in the future? So as to make the most correct decision